Published in J Addict Dis on January 01, 2002
The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci (2006) 2.46
Reactive oxygen species scavenger N-acetyl cysteine reduces methamphetamine-induced hyperthermia without affecting motor activity in mice. Temperature (Austin) (2015) 1.52
Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry (2008) 1.25
Is cognitive functioning impaired in methamphetamine users? A critical review. Neuropsychopharmacology (2011) 1.21
Methamphetamine increases brain viral load and activates natural killer cells in simian immunodeficiency virus-infected monkeys. Am J Pathol (2010) 1.09
An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans. Neuropsychopharmacology (2012) 1.09
Heterogeneity of stimulant dependence: a national drug abuse treatment clinical trials network study. Am J Addict (2009) 1.03
Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization. Psychopharmacology (Berl) (2005) 1.02
Comparison of intranasal methamphetamine and d-amphetamine self-administration by humans. Addiction (2012) 1.00
Anhedonia associated with stimulant use and dependence in a population-based sample of American adults. Exp Clin Psychopharmacol (2010) 0.98
The War on Drugs: Methamphetamine, Public Health, and Crime. Am Econ Rev (2009) 0.97
The effects of methamphetamine on core body temperature in the rat--part 1: chronic treatment and ambient temperature. Psychopharmacology (Berl) (2008) 0.96
Abnormal striatal circuitry and intensified novelty seeking among adolescents who abuse methamphetamine and cannabis. Dev Neurosci (2012) 0.95
Comparison of single-dose and extended methamphetamine administration on reversal learning in rats. Psychopharmacology (Berl) (2012) 0.91
Methamphetamine enhances Cryptococcus neoformans pulmonary infection and dissemination to the brain. MBio (2013) 0.90
Extended access to methamphetamine self-administration affects sensorimotor gating in rats. Behav Brain Res (2010) 0.90
Personality and the acute subjective effects of d-amphetamine in humans. J Psychopharmacol (2013) 0.89
Methamphetamine alters occludin expression via NADPH oxidase-induced oxidative insult and intact caveolae. J Cell Mol Med (2012) 0.88
Distributed attentional deficits in chronic methamphetamine abusers: evidence from the Attentional Network Task (ANT). Brain Cogn (2011) 0.87
Injury associated with methamphetamine use: a review of the literature. Harm Reduct J (2006) 0.87
Alterations in the striatal dopamine system during intravenous methamphetamine exposure: effects of contingent and noncontingent administration. Synapse (2013) 0.87
Methamphetamine alters blood brain barrier protein expression in mice, facilitating central nervous system infection by neurotropic Cryptococcus neoformans. J Infect Dis (2013) 0.86
Effects of the trace amine associated receptor 1 agonist RO5263397 on abuse-related behavioral indices of methamphetamine in rats. Int J Neuropsychopharmacol (2014) 0.86
An ethnographic exploration of self-reported violence among rural methamphetamine users. J Ethn Subst Abuse (2009) 0.83
Executive dysfunction and reward dysregulation: a high-density electrical mapping study in cocaine abusers. Neuropharmacology (2014) 0.82
Phenotypic changes in the brain of SIV-infected macaques exposed to methamphetamine parallel macrophage activation patterns induced by the common gamma-chain cytokine system. Front Microbiol (2015) 0.80
Unique genetic factors influence sensitivity to the rewarding and aversive effects of methamphetamine versus cocaine. Behav Brain Res (2013) 0.79
Extended-access, but not limited-access, methamphetamine self-administration induces behavioral and nucleus accumbens dopamine response changes in rats. Eur J Neurosci (2013) 0.79
Regulating task-monitoring systems in response to variable reward contingencies and outcomes in cocaine addicts. Psychopharmacology (Berl) (2016) 0.78
Predictors of depressive symptomatology among rural stimulant users. J Psychoactive Drugs (2010) 0.78
A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion. BMC Clin Pharmacol (2009) 0.78
Methamphetamine addiction: involvement of CREB and neuroinflammatory signaling pathways. Psychopharmacology (Berl) (2016) 0.78
Development of stereotyped behaviors during prolonged escalation of methamphetamine self-administration in rats. Psychopharmacology (Berl) (2012) 0.77
Doubling down: increased risk-taking behavior following a loss by individuals with cocaine use disorder is associated with striatal and anterior cingulate dysfunction. Biol Psychiatry Cogn Neurosci Neuroimaging (2017) 0.77
Methamphetamine Alters the Antimicrobial Efficacy of Phagocytic Cells during Methicillin-Resistant Staphylococcus aureus Skin Infection. MBio (2015) 0.76
A Mouse Model for Binge-Level Methamphetamine Use. Front Neurosci (2016) 0.76
Methamphetamine compromises gap junctional communication in astrocytes and neurons. J Neurochem (2016) 0.75
Retrograde conditioning of place preference and motor activity with cocaine in mice. Psychopharmacology (Berl) (2016) 0.75
Exercise protects against methamphetamine-induced aberrant neurogenesis. Sci Rep (2016) 0.75
"Tweaking and geeking, just having some fun": an analysis of methamphetamine poems. J Psychoactive Drugs (2010) 0.75
Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med (2003) 6.94
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet (2011) 6.35
Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci (2004) 4.14
Validation of the Alcohol, Smoking And Substance Involvement Screening Test (ASSIST). Addiction (2008) 3.98
The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs (2003) 3.91
Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry (2011) 3.15
Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry (2004) 3.02
DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry (2013) 2.89
Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict (2004) 2.85
A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Arch Gen Psychiatry (2002) 2.64
Smoking cessation in methadone maintenance. Addiction (2002) 2.62
Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. J Womens Health (Larchmt) (2009) 2.54
Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology (2007) 2.42
A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction (2006) 2.30
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction (2013) 2.23
Frontoparietal cortical activity of methamphetamine-dependent and comparison subjects performing a delay discounting task. Hum Brain Mapp (2007) 2.11
The methamphetamine problem in the United States. Annu Rev Public Health (2010) 2.00
Medications development: successes and challenges. Pharmacol Ther (2005) 1.80
HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr (2014) 1.79
A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev (2008) 1.77
Treatment for amphetamine withdrawal. Cochrane Database Syst Rev (2009) 1.75
Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend (2008) 1.73
A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology. Contemp Clin Trials (2010) 1.72
Working memory in cigarette smokers: comparison to non-smokers and effects of abstinence. Addict Behav (2005) 1.69
Drugs and sexual effects: role of drug type and gender. J Subst Abuse Treat (2002) 1.68
Will the methamphetamine problem go away? J Addict Dis (2002) 1.67
Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis (2002) 1.63
Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction (2013) 1.63
Naltrexone and dysphoria: fact or myth? Am J Addict (2002) 1.56
The gap between research and practice in substance abuse treatment. Psychiatr Serv (2002) 1.50
Methamphetamine abstinence syndrome: preliminary findings. Am J Addict (2004) 1.49
Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend (2006) 1.47
Brain activity in cigarette smokers performing a working memory task: effect of smoking abstinence. Biol Psychiatry (2005) 1.43
Opiate recidivism in a drug-treatment program: comparison of hair and urine data. J Anal Toxicol (2003) 1.43
Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend (2010) 1.41
Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers. Biol Psychiatry (2005) 1.40
Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction (2013) 1.39
Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend (2012) 1.37
Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry (2003) 1.36
Gender effects on mood and cigarette craving during early abstinence and resumption of smoking. Nicotine Tob Res (2008) 1.34
Psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug Alcohol Rev (2010) 1.32
Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment. J Subst Abuse Treat (2006) 1.31
Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse (2011) 1.29
Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs (2013) 1.22
Perspectives on decision making about human papillomavirus vaccination among 11- to 12-year-old girls and their mothers. Clin Pediatr (Phila) (2012) 1.21
Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs? J Subst Abuse Treat (2010) 1.21
The effect of relapse on cognition in abstinent methamphetamine abusers. J Subst Abuse Treat (2004) 1.19
Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region. Addiction (2002) 1.18
Long-term course of opioid addiction. Harv Rev Psychiatry (2015) 1.14
Buprenorphine 101: treating opioid dependence with buprenorphine in an office-based setting. J Addict Dis (2007) 1.13
Status of methamphetamine users 2-5 years after outpatient treatment. J Addict Dis (2002) 1.13
Predicting in-treatment performance and post-treatment outcomes in methamphetamine users. Addiction (2007) 1.12
A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. J Addict Med (2013) 1.11
Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics (2012) 1.10
Conducting clinical research with prescription opioid dependence: defining the population. Am J Addict (2010) 1.10
Management of methamphetamine abuse and dependence. Curr Psychiatry Rep (2006) 1.10
Traditional medicine in the treatment of drug addiction. Am J Drug Alcohol Abuse (2009) 1.09
Predicting treatment success at multiple timepoints in diverse patient populations of cocaine-dependent individuals. Drug Alcohol Depend (2002) 1.08
Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. Drug Alcohol Depend (2008) 1.07
Identifying predictors of treatment outcome in a drug court program. Am J Drug Alcohol Abuse (2005) 1.05
Alcohol and drug dependence symptom items as brief screeners for substance use disorders: results from the Clinical Trials Network. J Psychiatr Res (2011) 1.04
Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers. Clin Neurophysiol (2004) 1.03
Health-related quality of life trajectories of methamphetamine-dependent individuals as a function of treatment completion and continued care over a 1-year period. J Subst Abuse Treat (2009) 1.03
Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoactive Drugs (2014) 1.00
Pain and continued opioid use in individuals receiving buprenorphine-naloxone for opioid detoxification: secondary analyses from the Clinical Trials Network. J Subst Abuse Treat (2010) 0.99
Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend (2006) 0.99
Gender and racial/ethnic differences in addiction severity, HIV risk, and quality of life among adults in opioid detoxification: results from the National Drug Abuse Treatment Clinical Trials Network. Subst Abuse Rehabil (2010) 0.98
Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug Alcohol Depend (2005) 0.97
Irritability following abstinence from cocaine predicts euphoric effects of cocaine administration. Addict Behav (2003) 0.97
An emerging problem: methamphetamine abuse among treatment seeking youth. Subst Abus (2008) 0.97
Levo-alpha-acetylmethadol (LAAM) versus methadone: treatment retention and opiate use. Addiction (2005) 0.96
Dancing with strangers: will U.S. substance abuse practice and research organizations build mutually productive relationships? Addict Behav (2002) 0.96
Eight weeks of exercise training improves fitness measures in methamphetamine-dependent individuals in residential treatment. J Addict Med (2013) 0.96
Depressive symptoms, substance use, and HIV-related high-risk behaviors among opioid-dependent individuals: results from the Clinical Trials Network. Subst Use Misuse (2011) 0.95
Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology. J Addict Dis (2002) 0.94
Predictors of outcome after short-term stabilization with buprenorphine. J Subst Abuse Treat (2012) 0.94
Comparing buprenorphine induction experience with heroin and prescription opioid users. J Subst Abuse Treat (2012) 0.93
Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals. Clin Neurophysiol (2003) 0.92
An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology (2013) 0.92
Gabapentin improves cold-pressor pain responses in methadone-maintained patients. Drug Alcohol Depend (2010) 0.92
A comparison of four telephone-based counseling styles for recovering stimulant users. Psychol Addict Behav (2012) 0.92
Participant characteristics and buprenorphine dose. Am J Drug Alcohol Abuse (2011) 0.91
Prescription and over-the-counter drug treatment admissions to the California public treatment system. J Subst Abuse Treat (2010) 0.90
Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. J Addict Dis (2008) 0.90
Treatment for amphetamine psychosis. Cochrane Database Syst Rev (2009) 0.90